Pharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Pharvaris (PHVS) detailed its strategic outlook for deucrictibant, an oral B2 receptor antagonist for Hereditary Angioedema (HAE), at the Cantor Global Healthcare Conference. The company anticipates key Phase III data for its on-demand HAE program in Q4 2025, with a U.S. filing targeted for H1 2026 and potential launch in early 2027. Deucrictibant aims to offer injectable-like efficacy with oral convenience across both on-demand and prophylaxis settings, leveraging an optimized extended-release formulation for the latter, and is uniquely positioned to address broader bradykinin-mediated angioedema, including underserved acquired angioedema patients, due to its downstream mechanism.

Analysis

Pharvaris N.V. (PHVS) is positioning its oral drug, deucrictibant, as a potential best-in-class treatment for Hereditary Angioedema (HAE), aiming to combine injectable-like efficacy with the convenience of an oral tablet. The company's strategy hinges on several key upcoming catalysts, most notably the Phase III data for the on-demand HAE indication expected in Q4 2025, followed by a targeted U.S. filing in H1 2026 and a potential launch in early 2027. Management expressed high confidence in replicating strong Phase II results, which would differentiate deucrictibant from the current oral standard-of-care, Orladeyo, by not forcing a trade-off between efficacy and convenience. For the larger prophylaxis market, Pharvaris is leveraging an extended-release formulation designed to optimize the pharmacokinetic profile, which may enhance efficacy and long-term safety, with pivotal data expected in the second half of 2026. A key differentiator is deucrictibant's unique mechanism as a downstream B2 receptor antagonist, which not only provides a competitive advantage within HAE but also opens a strategic pathway to treat a broader population of underserved patients with bradykinin-mediated angioedema, such as acquired angioedema, a market with no currently approved therapies.

Key Decisions for Investors

• Investors should view the Phase III on-demand trial data, expected in Q4 2025, as the most critical near-term catalyst, where confirmation of injectable-like efficacy would significantly de-risk the asset and validate its competitive profile.
• The larger commercial opportunity resides in the prophylaxis setting, where an optimized extended-release formulation could position deucrictibant as a dominant oral therapy, making the H2 2026 data readout a key inflection point for long-term valuation.
• Evaluate the company's unique strategic advantage in targeting a broader population of bradykinin-mediated angioedema, as the planned CREATE study could unlock a currently underserved market and provide a key differentiator from all HAE-focused competitors.
• Consider the well-defined commercial strategy targeting four distinct patient segments, as successful execution against Orladeyo dropouts and patients on injectables will be crucial for market penetration following the anticipated early 2027 launch.